Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress. At the ...
The FDA granted priority review for enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy. The KEYNOTE-905/EV-303 trial ...
Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response rates and prolonged progression-free survival. Arm 4 demonstrated a median ...
An expert discusses how comparing the durability and treatment effects of newer minimally invasive therapies to gold standard transurethral resection of the prostate (TURP) or holmium laser ...
Chan shares how her passion for research and desire to impact patients on a broader scale led her from academia to industry. In this episode of Pearls & Perspectives, host Amy Pearlman, MD, welcomes ...
Srikala Sridhar, MD, MSc, FRCPC, outlines phase 2 data on avelumab in patients with locally advanced or metastatic penile cancer. The study included a total of 23 patients with a median age of 59 ...
Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising ...
The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...
Incorporating mpMRI before TURBT improves bladder cancer-specific survival in patients with suspected MIBC. The BladderPath trial aimed to reduce time to radical treatment by comparing mpMRI before ...
Adjuvant durvalumab plus tremelimumab improved DFS in resected RCC, especially in high-risk patients, with a 43% reduction in recurrence risk. The trial enrolled patients into three arms, with the ...
Panelists discuss how real-world evidence confirms IsoPSA’s predictive value, showing that high scores align with significantly greater long-term cancer risk. Panelists discuss how real-world trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback